Prosecution Insights
Last updated: April 19, 2026
Application No. 18/259,677

EXTRACTS FROM OIL SEEDS AND METHODS FOR PROCESSING OIL SEEDS

Non-Final OA §102§103§112
Filed
Jun 28, 2023
Examiner
MORNHINWEG, JEFFREY P
Art Unit
1793
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Sunflower Holdco, Inc.
OA Round
1 (Non-Final)
36%
Grant Probability
At Risk
1-2
OA Rounds
3y 11m
To Grant
70%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
200 granted / 558 resolved
-29.2% vs TC avg
Strong +34% interview lift
Without
With
+33.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
62 currently pending
Career history
620
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
48.8%
+8.8% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 558 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application The status of the claims stands as follows: Pending claims: 39-58 Canceled claims: 1-38 Currently rejected claims: 39-58 Allowed claims: None Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 43 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 43 recites the limitation “the permeate” in line 9. There is insufficient antecedent basis for this limitation in the claim. Note the claim recites multiple subsequent instances of permeates already defined as “a permeate” and “a second permeate”. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 39 and 51-54 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Defaix et al. (WO 2019/096862 A1). Regarding claim 39, Defaix et al. discloses a method for extracting a plurality of target materials from oil seeds (p. 3, ll. 15-17), the method comprising: performing an extraction on an oil seed material to form an aqueous phase and a solid phase, wherein the extraction is performed in an organic solvent-free extraction at a pH of 5-8 (p. 3, ll. 23-27; p. 4, ll. 18-28); separating the insoluble solids from the aqueous phase (p. 3, l. 28); filtering the aqueous phase into a retentate and a permeate (p. 4, ll. 8-9; p. 9, ll. 25-31); and drying the retentate (p. 4, l. 10). Regarding claim 51, Defaix et al. discloses a composition comprising a first component comprising a protein extract that is isolated from oil seeds after at least one extraction process at a pH of 5-8 and a second component comprising phytic acid (p. 3, ll. 20-28), where the oil seed may be sunflower seed (p. 16, ll. 16-19). As for claim 52, Defaix et al. discloses the first component as comprising 91.7-99 wt.% of the composition (p. 14, ll. 10-14). As for claim 53, Defaix et al. discloses the second component as comprising 0.28-7.7 wt.% of the composition (p. 3, ll. 21-23). As for claim 54, Defaix et al. discloses the second component as comprising 2.6 wt.% of the composition (p. 3, ll. 21-23). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 40-49 and 55-58 are rejected under 35 U.S.C. 103 as being unpatentable over Defaix et al. (WO 2019/096862 A1). As for claims 40-42, Defaix et al. disclose the method of claim 39. Defaix et al. does not disclose the retentate as having the claimed sweetness. However, MPEP 2112.01 I states: “Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established.” Since Defaix et al. discloses producing the material by a substantially identical process as that claimed, the obtained retentate would have the same properties as those presently claimed, which renders the claimed limitations requiring the retentate to have a sweetness that is (i) sweeter than that of sucrose (claim 40); (ii) 2-10 times sweeter than that of sucrose (claim 41), or (iii) 2-5 times sweeter than that of sucrose (claim 42) obvious to a skilled practitioner. Further, the present claims do not require (i) the sweetness of the retentate to be due exclusively to whatever material is harvested from the oil seed material, or (ii) any concentration of the sweet-tasting material in the retentate. To the extent a retentate may potentially be obtained that does not exhibit the claimed sweetness, the retentate may simply be sweetened via the addition of a high-potency sweetener to obtain the claimed sweetness as is well-known in the art. Regarding claim 43, Defaix et al. discloses a method for extracting materials from oil seeds (p. 3, ll. 15-17), the method comprising: mixing an extraction solution that includes water and a salt and has a pH of 5-8 (p. 3, ll. 23-27; p. 4, ll. 18-28) with a quantity of oils seeds that have been dehulled (p. 16, ll. 13-14), cold-pressed (p. 15, ll. 12-13), and milled (p. 15, ll. 3-4) to form a mixture (p. 4, ll. 33-36); extracting the mixture at a temperature in the range of 10-93°C (p. 4, l. 33 – p. 5, l. 3) for 0.5-6 hours (p. 5, ll. 6-8) to form an extracted mixture having an aqueous phase; separating the insoluble solids from the aqueous phase using a separation process (p. 3, l. 28; p. 5, ll. 23-28); lowering the pH of a mixture comprising dissolved proteins to within the range of 4.0-4.5 (specifically, “from 1 to 4”) (p. 6, ll. 25-28, l. 37), which is presumed to create a precipitate; sequentially filtering the insoluble solids material to obtain a protein target material in a retentate (p. 4, ll. 8-9; p. 9, l. 25 – p. 10, l. 5; p. 10, ll. 22-23, where filtration steps may be repeated); and drying the retentate (p. 4, l. 10; p. 10, ll. 13-15). Defaix et al. does not disclose lowering the pH of the permeate in particular or the specific filtration steps of (i) filtering the lowered pH material to form a retentate and a permeate; (ii) drying the retentate to form a dried retentate that comprises a first target material; (iii) filtering the permeate to form a second retentate and a second permeate; (iv) drying the second retentate to form a dried second retentate that comprises a second target material; (v) filtering the second permeate to form a third retentate; and (vi) drying the third retentate to form a dried third retentate that comprises a third target material. However, the instruction in Defaix et al. that the liquid phase may be subject to “one or several membrane filtration(s) to obtain a protein isolate” (p. 4, ll. 8-9) and that the separation/filtration steps may be repeated (p. 10, ll. 22-23) renders the claimed repetition of filtration steps in order to obtain target materials obvious. Further, the material which is subjected to a lowered pH contains the target protein material (p. 6, ll. 25-28). Subjecting any fraction containing the target material to subsequent processing in order to further purify the material would be obvious. As such, the claimed step of lowering the pH of the permeate obtained after separating insoluble solids from an aqueous phase would be obvious due to comprising dissolved protein material. As for claims 44 and 45, Defaix et al. discloses the target material includes protein (p. 9, ll. 25-27). Obtaining first or second target materials that comprise proteins from first or second retentates would thus be obvious. As for claim 46, Defaix et al. discloses adding a precipitating material to the aqueous phase to form a precipitate (p. 8, ll. 15-28; p. 7, ll. 28-29; p. 8, l. 34 – p. 9, l. 2). As for claim 47, Defaix et al. discloses removal of phytic acid via precipitation (p. 8, ll. 15-28; p. 7, ll. 28-29; p. 8, l. 34 – p. 9, l. 2), such that the precipitate is presumed to include phytic acid. As for claim 48, Defaix et al. discloses adding calcium chloride to the aqueous phase as a precipitating material (p. 8, ll. 15-16; p. 7, ll. 28-29). As for claim 49, Defaix et al. discloses adding calcium chloride to the aqueous phase as a precipitating material (p. 8, ll. 15-16; p. 7, ll. 28-29) in a molar concentration ranging from 0.01 M to 2 M, with a “concentration of around 0.5 M ± 10% ha[ving] shown particular efficacy” (p. 8, ll. 15-20). Such evidence of optimization suggests to a skilled practitioner that an optimized molar ratio between calcium chloride and phytic acid may be determined via routine experimentation. MPEP 2144.05 II. As for claims 55-58, Defaix et al. discloses the composition of claim 51. Defaix et al. does not disclose the composition as having the claimed sweetness. However, MPEP 2112.01 I states: “Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established.” Since Defaix et al. discloses producing the material by a substantially identical process as that claimed, the obtained retentate would have the same properties as those presently claimed, which renders the claimed limitations requiring the composition to have a sweetness that is (i) substantially equal to a sweetness of sucrose (claim 55),; (ii) sweeter than that of sucrose (claim 56); (iii) 2-10 times sweeter than that of sucrose (claim 57), or (iv) 2-5 times sweeter than that of sucrose (claim 58) obvious to a skilled practitioner. Further, the present claims do not require (i) the sweetness of the composition to be due exclusively to whatever material is harvested from the oil seed material, or (ii) any concentration of the sweet-tasting material in the extracted material. To the extent a composition may potentially be obtained that does not exhibit the claimed sweetness, the composition may simply be sweetened via the addition of sucrose (claim 55) or a high-potency sweetener (claims 56-58) to obtain the claimed sweetness as is well-known in the art. Claim 50 is rejected under 35 U.S.C. 103 as being unpatentable over Defaix et al. (WO 2019/096862 A1) in view of Pearce (U.S. 4,435,319). As for claim 50, Defaix et al. discloses the method of claim 43. Defaix et al. does not specifically disclose separation of chlorogenic acid as part of a filtration retentate. However, Pearce discloses chlorogenic acid as being a polyphenol present in sunflower seed extract that contributes to dark, undesirable color characteristics (c. 1, l. 60 – c. 2, l. 2). It would have been obvious to one having ordinary skill in the art to separate chlorogenic acid as part of a filtration retentate when practicing the method of Defaix et al. First, the reference indicates that filtration may be used to separate phenolic compounds without clarifying specific types of phenolic compounds (p. 9, ll. 28-30). A skilled practitioner would be motivated to consult Pearce for clarification of such types of compounds and would determine that chlorogenic acid in particular results in undesirable color characteristics (c. 1, l. 60 – c. 2, l. 2). As such, performing filtration in order to separate chlorogenic acid from the sunflower extract would be obvious to a skilled practitioner. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEFFREY P MORNHINWEG whose telephone number is (571)270-5272. The examiner can normally be reached 8:30AM-5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEFFREY P MORNHINWEG/Primary Examiner, Art Unit 1793
Read full office action

Prosecution Timeline

Jun 28, 2023
Application Filed
Jan 22, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599157
NATURAL SWEETENING FLAVOR COMPOSITION
2y 5m to grant Granted Apr 14, 2026
Patent 12550923
ALLULOSE SYRUPS
2y 5m to grant Granted Feb 17, 2026
Patent 12520863
Compositions used for sweetened substances
2y 5m to grant Granted Jan 13, 2026
Patent 12514274
GRANULATION OF A STEVIA SWEETENER
2y 5m to grant Granted Jan 06, 2026
Patent 12490754
WHEY PROTEIN-BASED, HIGH PROTEIN, YOGHURT-LIKE PRODUCT, INGREDIENT SUITABLE FOR ITS PRODUCTION, AND METHOD OF PRODUCTION
2y 5m to grant Granted Dec 09, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
36%
Grant Probability
70%
With Interview (+33.7%)
3y 11m
Median Time to Grant
Low
PTA Risk
Based on 558 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month